Drug intelligence / Profile preview

MAb51-31

Development stage: Unknown
Lead developer: MedAbome
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

MAb51-31 is a monoclonal antibody developed by Medabome for the treatment of neoplasms, specifically targeting solid tumors. As of May 2025, its highest global R&D status is at the Discovery stage. The precise molecular target and mechanism of action have not been disclosed publicly. The drug is being investigated as an immunotherapeutic agent in oncology, but no clinical trial results or detailed mechanistic data are available yet.

Other names: MAb 51-31-ADCMAb51-31-ADCMAb-51-31-ADC

Targets

Neuraminidase

Beyond the preview

Go deeper on MAb51-31.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MAb51-31.

Explore the full profile